The genetics of antiplatelet drug resistance

G. Fehér, A. Feher, G. Pusch, G. Lupkovics, L. Szapáry, E. Papp

Research output: Article

64 Citations (Scopus)

Abstract

Platelets have a central role in the development of arterial thrombosis and subsequent cardiovascular events. An appreciation of this complex process has made antiplatelet therapy the cornerstone of cardiovascular disease management. However, numerous patients will experience a recurrent atherothrombotic vascular event despite adequate antiplatelet therapy. Individual differences in the rate of platelet activation and reactivity markedly influence normal hemostasis and the pathological outcome of thrombosis. Such an individual variability is largely determined by environmental and genetic factors. These are known to either hamper platelets' response to agonists, and thereby mimic the pharmacological modulation of platelet function or mask therapy effect and sensitize platelets. In this article, we reviewed the antiplatelet mechanisms of aspirin and clopidogrel and the possible role of different polymorphisms, which may affect the efficacy of antiplatelet therapy. Heterogeneity in the way patients respond to aspirin and clopidogrel may in part reflect variation in cyclooxygenase (COX)-1, COX-2, glycoprotein (GP) Ib alpha, GP Ia/IIa, GP IIb/IIIa, UGT1A6*2, P2Y1, P2Y12, CYP2C9, CYP3A4 and CYP3A5 genotypes.

Original languageEnglish
Pages (from-to)1-18
Number of pages18
JournalClinical Genetics
Volume75
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

clopidogrel
Platelet Aggregation Inhibitors
Drug Resistance
Blood Platelets
Cytochrome P-450 CYP3A
Aspirin
Integrin alpha2beta1
Thrombosis
Platelet Glycoprotein GPIb-IX Complex
Cyclooxygenase 1
Platelet Glycoprotein GPIIb-IIIa Complex
Platelet Activation
Cyclooxygenase 2
Therapeutics
Disease Management
Masks
Hemostasis
Individuality
Blood Vessels
Cardiovascular Diseases

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

The genetics of antiplatelet drug resistance. / Fehér, G.; Feher, A.; Pusch, G.; Lupkovics, G.; Szapáry, L.; Papp, E.

In: Clinical Genetics, Vol. 75, No. 1, 2009, p. 1-18.

Research output: Article

Fehér, G. ; Feher, A. ; Pusch, G. ; Lupkovics, G. ; Szapáry, L. ; Papp, E. / The genetics of antiplatelet drug resistance. In: Clinical Genetics. 2009 ; Vol. 75, No. 1. pp. 1-18.
@article{e821138f466742d6b042480089b26dfc,
title = "The genetics of antiplatelet drug resistance",
abstract = "Platelets have a central role in the development of arterial thrombosis and subsequent cardiovascular events. An appreciation of this complex process has made antiplatelet therapy the cornerstone of cardiovascular disease management. However, numerous patients will experience a recurrent atherothrombotic vascular event despite adequate antiplatelet therapy. Individual differences in the rate of platelet activation and reactivity markedly influence normal hemostasis and the pathological outcome of thrombosis. Such an individual variability is largely determined by environmental and genetic factors. These are known to either hamper platelets' response to agonists, and thereby mimic the pharmacological modulation of platelet function or mask therapy effect and sensitize platelets. In this article, we reviewed the antiplatelet mechanisms of aspirin and clopidogrel and the possible role of different polymorphisms, which may affect the efficacy of antiplatelet therapy. Heterogeneity in the way patients respond to aspirin and clopidogrel may in part reflect variation in cyclooxygenase (COX)-1, COX-2, glycoprotein (GP) Ib alpha, GP Ia/IIa, GP IIb/IIIa, UGT1A6*2, P2Y1, P2Y12, CYP2C9, CYP3A4 and CYP3A5 genotypes.",
keywords = "Aspirin, Clopidogrel, Genetical polymorphism, Resistance, Variability",
author = "G. Feh{\'e}r and A. Feher and G. Pusch and G. Lupkovics and L. Szap{\'a}ry and E. Papp",
year = "2009",
doi = "10.1111/j.1399-0004.2008.01105.x",
language = "English",
volume = "75",
pages = "1--18",
journal = "Clinical Genetics",
issn = "0009-9163",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The genetics of antiplatelet drug resistance

AU - Fehér, G.

AU - Feher, A.

AU - Pusch, G.

AU - Lupkovics, G.

AU - Szapáry, L.

AU - Papp, E.

PY - 2009

Y1 - 2009

N2 - Platelets have a central role in the development of arterial thrombosis and subsequent cardiovascular events. An appreciation of this complex process has made antiplatelet therapy the cornerstone of cardiovascular disease management. However, numerous patients will experience a recurrent atherothrombotic vascular event despite adequate antiplatelet therapy. Individual differences in the rate of platelet activation and reactivity markedly influence normal hemostasis and the pathological outcome of thrombosis. Such an individual variability is largely determined by environmental and genetic factors. These are known to either hamper platelets' response to agonists, and thereby mimic the pharmacological modulation of platelet function or mask therapy effect and sensitize platelets. In this article, we reviewed the antiplatelet mechanisms of aspirin and clopidogrel and the possible role of different polymorphisms, which may affect the efficacy of antiplatelet therapy. Heterogeneity in the way patients respond to aspirin and clopidogrel may in part reflect variation in cyclooxygenase (COX)-1, COX-2, glycoprotein (GP) Ib alpha, GP Ia/IIa, GP IIb/IIIa, UGT1A6*2, P2Y1, P2Y12, CYP2C9, CYP3A4 and CYP3A5 genotypes.

AB - Platelets have a central role in the development of arterial thrombosis and subsequent cardiovascular events. An appreciation of this complex process has made antiplatelet therapy the cornerstone of cardiovascular disease management. However, numerous patients will experience a recurrent atherothrombotic vascular event despite adequate antiplatelet therapy. Individual differences in the rate of platelet activation and reactivity markedly influence normal hemostasis and the pathological outcome of thrombosis. Such an individual variability is largely determined by environmental and genetic factors. These are known to either hamper platelets' response to agonists, and thereby mimic the pharmacological modulation of platelet function or mask therapy effect and sensitize platelets. In this article, we reviewed the antiplatelet mechanisms of aspirin and clopidogrel and the possible role of different polymorphisms, which may affect the efficacy of antiplatelet therapy. Heterogeneity in the way patients respond to aspirin and clopidogrel may in part reflect variation in cyclooxygenase (COX)-1, COX-2, glycoprotein (GP) Ib alpha, GP Ia/IIa, GP IIb/IIIa, UGT1A6*2, P2Y1, P2Y12, CYP2C9, CYP3A4 and CYP3A5 genotypes.

KW - Aspirin

KW - Clopidogrel

KW - Genetical polymorphism

KW - Resistance

KW - Variability

UR - http://www.scopus.com/inward/record.url?scp=58149189837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149189837&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0004.2008.01105.x

DO - 10.1111/j.1399-0004.2008.01105.x

M3 - Article

C2 - 19067731

AN - SCOPUS:58149189837

VL - 75

SP - 1

EP - 18

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 1

ER -